MDWD News and Press, MediWound Ltd. From 05/17/22

Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference C all B egins T oday at 8:30 am ET YAVNE, Israel, May 17, 2022 (GLOBE NE...

MediWound (NASDAQ:MDWD) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.11 (-10.0% Y/Y) and the consensus Revenue Estimate is $4.29M (-26.7% Y/Y). Over the last 1 year, MDWD has beaten EPS estimates 75% of the time and h...

Study Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety I...

YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fi...

YAVNE, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that clinical data from the Company’s EscharEx ®...

Gainers: Sabre Corporation (SABR) +11%. Kura Sushi USA  (KRUS) +11%. WD-40 Company (WDFC) +10%. MediWound  (MDWD) +7%. Cognyte Software  (CGNT) +5%. Losers: OraSure Technologies (OSUR) -5%. Momentus  (MNTS) -5%. Icosavax  (ICVX) -5%. Berkeley ...

Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generat...

YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announ...

Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio...

MediWound Ltd. (MDWD) Q4 2021 Earnings Conference Call March 17, 2022 08:30 ET Company Participants Monique Kosse - Investor Relations Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Kevin DeGeeter - Oppenheime...